Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator

被引:33
作者
Mohanam, S
Chandrasekar, N
Yanamandra, N
Khawar, S
Mirza, F
Dinh, DH
Olivero, WC
Rao, JS
机构
[1] Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA
关键词
ATF; uPA; glioblastoma; invasiveness;
D O I
10.1038/sj.onc.1205893
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.
引用
收藏
页码:7824 / 7830
页数:7
相关论文
共 27 条
[11]   Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice [J].
Li, H ;
Lu, H ;
Griscelli, F ;
Opolon, P ;
Sun, LQ ;
Ragot, T ;
Legrand, Y ;
Belin, D ;
Soria, J ;
Soria, C ;
Perricaudet, M ;
Yeh, P .
GENE THERAPY, 1998, 5 (08) :1105-1113
[12]   In vitro anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells [J].
Luparello, C ;
DelRosso, M .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (04) :702-707
[13]  
Min HY, 1996, CANCER RES, V56, P2428
[14]  
Mohanam S, 2001, CLIN CANCER RES, V7, P2519
[15]   In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor [J].
Mohanam, S ;
Chintala, SK ;
Go, Y ;
Bhattacharya, A ;
Venkaiah, B ;
Boyd, D ;
Gokaslan, ZL ;
Sawaya, R ;
Rao, JS .
ONCOGENE, 1997, 14 (11) :1351-1359
[16]  
MOHANAM S, 1993, CANCER RES, V53, P4143
[17]   Binding of human urokinase-type plasminogen activator to its receptor - Residues involved in species specificity and binding [J].
Quax, PHA ;
Grimbergen, JM ;
Lansink, M ;
Bakker, AHF ;
Blatter, MC ;
Belin, D ;
van Hinsbergh, VWM ;
Verheijen, JH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (05) :693-701
[18]   Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels [J].
Quax, PHA ;
Lamfers, MLM ;
Lardenoye, JHP ;
Grimbergen, JM ;
de Vries, MR ;
Slomp, J ;
de Ruiter, MC ;
Kockx, MM ;
Verheijen, JH ;
van Hinsbergh, VWM .
CIRCULATION, 2001, 103 (04) :562-569
[19]  
RABBANI SA, 1992, J BIOL CHEM, V267, P14151
[20]  
Reuning U, 1998, INT J ONCOL, V13, P893